Untitled

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough. The facility represents a significant expansion in Kindeva’s MDI services and will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly products.

Nestled in the heart of Loughborough’s Technology Park, the 150,000 sq. ft. site offers a range of services across drug development, from early-stage viability, analytical method development, to commercial analysis. Boasting a Chemistry, Manufacturing and Controls (CMC) strategy and regulatory department to guide customers through complex compliance hurdles, the facility will support customers at every stage of the drug development journey.

The official opening will be marked with a launch event hosted by the CEO of Kindeva, Milton Boyer and David Northage, Mayor of Charnwood. A ribbon-cutting ceremony will be followed by a site tour, where Kindeva will unveil its investment and recruitment strategy for the future.

Commenting on the new site, Milton Boyer said: “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”

The Loughborough HQ will be responsible for developing and analysing NGPs as the industry faces significant legislation aimed at reducing the environmental impact of the propellants currently used in pressurized metered-dose inhalers (pMDIs).

Boyer continued: “Research estimates that inhalers contribute to 0.03% of total global greenhouse gas emissions, and represent 3% of the U.K. National Health Service (NHS) carbon footprint. Investment in our Loughborough site, new technologies and people, will allow Kindeva to become the leading force in the industry for sustainability and assuring supply continuity as the industry transitions to low Global Warming Potential (GWP) propellants.”

Kindeva is a leading global CDMO with vast expertise in drug delivery devices.

Hundreds of entries received across 14 categories showcasing innovation, sustainability, and leadership in pharma

Informa Markets, has today announced the shortlist for the CPHI Pharma Awards 2025, recognising outstanding achievements across pharmaceutical innovation, manufacturing, sustainability, leadership and women in pharma.

The awards spotlight the companies and individuals pushing the boundaries of science and technology to advance global healthcare.

The CPHI Pharma Awards finalists for 2025 include innovators redefining everything from synthetic biology and AI-powered formulation to patient access, circular packaging, and leadership in rare diseases, spotlighting the most transformative work happening in the industry today.

This year’s shortlist also celebrates the next generation of pharmaceutical changemakers through the Future Leader and Women in Pharma categories, spotlighting individuals whose impact and vision are reshaping the industry from within.

“We’ve been incredibly impressed by the quality, originality, and ambition of this year’s submissions. Across every category, the finalists are setting new standards in pharmaceutical innovation, sustainability, and patient impact. The CPHI Pharma Awards are a vital platform to spotlight the progress shaping the future of our industry. We’re looking forward to celebrating these achievements and announcing the winners on the opening day of CPHI Frankfurt.” Tara Dougal, CPHI Event Director, Informa Markets.

The winners will be revealed during an exclusive networking reception on October 28 — the opening day of CPHI Frankfurt 2025, held at Messe Frankfurt from October 28–30.

Finalists by Category

The full list of 2025 finalists is available by category below. Further information on each finalist can be found here:

API Development and Innovation

Lonza: Design2Optimize(™)

CMAC: From Crystallisation to tablet: A scalable Platform for API Agglomeration.

Merck KgaA: mPredict Co-crystal Prediction Service

CordenPharma International: TAPS: TAG Assisted Peptide Synthesis.

Accelerating Innovation

NunaBio Ltd: Custom, cell-free, synthetic DNA

TriLink Biotechnologies: GMP-Grade CleanCap® M6 Analog

Covestro Deutschland AG: Mono-Material Drug Delivery Demonstrator

Accord Healthcare: Orgovyx — Transforming prostate cancer care

Invengene Private Limited: Room temperature-stable generic Posaconazole Injection Using Hydroxypropyl beta-cyclodextrin (HPβCD)

Prestige BioPharma: Ullenistamab: A Targeted MAB for pancreatic cancer.

At the Heart of Pharma

Accord Healthcare: A decade of impact with International Health Partners (IHP)

PharmEvo Pvt. Ltd: Elevating patient safety through intelligent design

Strides: Enhancing access to affordable healthcare — HIV

Farmak International: Resilient by Design: Farmak Group’s Ukrainian-rooted pharma network blueprint for crisis-proof global supply

CNX Therapeutics and the Social Mobility Foundation: Talent without barriers.

CEO of the Year

Bobby Sheng: Bora Pharmaceuticals

Deepak Bahri: Sentiss Pharma

Hanns-Christian Mahler: ten23 health

Lars Petersen: FUJIFILM Diosynth Biotechnologies

Lisa Soyeon Park: Prestige Biopharma

Michael Quirmbach: CordenPharma International.

Drug Delivery and Device Innovation

Azelis Group NV: Advanced Peristomal Barrier & Adhesion Cream

SHL Medical: Maggie® Mix: A dual-chamber autoinjector with Needle Isolation Technology (NIT®)

LTS Lohmann Therapie Systems AG: Launching the first biosimilar in an on-body injector

Ypsomed: Uniting sustainability and patient convenience in self-injection devices.

Finished Formulation

Zerion Pharma A/S: Dispersome® technology

Evonik Industries AG: EUDRACAP® colon: The world’s first functional ready-to-fill capsule for oral drug delivery to target the ileo-colonic region

CrystecPharma: Modified Supercritical Anti-Solvent (mSAS®) particle engineering for stabilisation of biomolecules

Roquette: ReadiLYCOAT® Plant-Based Coating Systems for enhanced oral dosage solutions

Lonza Capsules & Health Ingredients: Innovaform® Innovation and formulation accelerator.

Future Leader

Jakub Knurek: Mabion

Mark Kelada: Nelipak Laboratory Services

Mohammad Farahani: CinnaGen

Yolanda Gomez: Esteve CDMO

Yuvansh Khokhani:YSK Laboratories Pvt Ltd.

Manufacturing Excellence

Coriolis Pharma Research GmbH: Advanced lyophilization modelling

Enzene: EnzeneX™: Fully-connected continuous manufacturing™

Bausch+Ströbel SE + Co. KG: GENEX, robotic, modular aseptic fill-finish platform

VectorBuilder: VectorBuilder’s gene drug manufacturing platform.

Packaging and Machinery

SCHOTT Pharma: SCHOTT TOPPAC® infuse — the next generation IMA LIFE: TILE-X: New generation gloveless aseptic fill-finish system

H&T Presspart: Vytal® innovative RTU snap-fit closure.

Start-Up Initiative

Green Elephant Biotech: CellScrew®

NunaBio Ltd: Custom: Cell-free, synthetic DNA — including high complexity sequences, multi kilobase length and milligram scale — made in days to weeks

NovoArc GmbH: Lipids for innovative drug formulation

ORYL Photonics: ORYL F1.

Supply Chain Excellence

Cryoport Systems: Integrated end-to-end supply chain platform

Occam Systems: Resilient chemical supply chains, supercharged by AI

QYOBO GmbH: QYOBO platform

TraceLink: TraceLink Orchestration Platform for Universal Solutions (OPUS).

Sustainability

Celtic Renewables: Leading the Green Chemical Revolution, transforming industrial by-products into high-value green chemicals.

Enantios: Enantios platform — Enabling fast, label-free chiral analysis in solution

Avantor: J.T.Baker® Viral Inactivation Solution — Environmentally safer detergent for virus removal in bioprocessing

AustinPx: KinetiSol™ Technology, a solvent-free, fusion-based technology that transforms poorly soluble drugs into high-bioavailability formulations

Kindeva: Leading the way in next-generation propellants (NGPs) — commercial-ready capabilities in HFA152a and HFO1234ze propellants.

Alliance to Zero: Lean, Green and Secure, a regulatory-ready, blister-free, syringe solution

Huhtamaki: Omnilock™ Ultra PAPER

Botanical Solution Inc. (BSI): Sustainability Grows on Trees: Producing QS-21, the Gold Standard vaccine adjuvant.

Woman of the Year

Adriana Kiędzierska-Mencfeld, Polpharma Biologics

Christiane Bardroff, Rentschler Biopharma

Ivy Gao, Sunresin

Jennifer Gattari, Pfizer CentreOne

Jonina Gudmundsdottir, Coripharma

Meeta Gulyani, Ecolab Life Sciences.

Partnership delivers global, end-to-end solutions to accelerate genomics research

Sapio Sciences, the science-awareTM lab informatics platform, today announced a strategic partnership with Ultima Genomics. The collaboration will make multi-omics workflows more accessible and streamlined for researchers by integrating Sapio’s AI-powered lab informatics solutions with Ultima’s high-throughput, low-cost sequencing platform. Together, the companies will deliver efficient, traceable, and unified workflows for multi-omics research and clinical genomics.

Ultima Genomics is known for its innovative ultra-high throughput sequencing architecture, designed to drive down sequencing costs and scale beyond conventional technologies. Its multiomics sequencing capabilities allow researchers to study layers of biology beyond DNA sequences alone. Many changes linked to disease occur first in other omic layers, such as in the epigenome with cancer.

Deeper levels of analysis are increasingly important for understanding complex biology, but until now have often required multiple costly assays and fragmented workflows. This integration allows researchers and clinicians to combine Ultima’s data generation capabilities with Sapio’s analytics, automation, and data management tools for a seamless, end-to-end solution.

Gilad Almogy, CEO and founder of Ultima Genomics, commented, “Partnering with Sapio Sciences aligns with our goals to enable leading sequencing labs and make genomic information more scalable. By integrating our high-throughput, low-cost sequencing platform with Sapio’s AI-powered lab informatics platform, we’re enabling a seamless, scalable solution for multi-omics research and clinical genomics.

Almogy continued, “We’re excited to empower organizations to accelerate discovery, drive AI-powered insights, and bring high-quality genomics into everyday workflows with unmatched efficiency and traceability.”

Key Benefits for Customers

Integrated workflows: Unify sequencing and informatics into a single environment, so researchers avoid fragmented assays.

Lower cost per sample: Reduce per-sample costs with ultra-high throughput sequencing.

Faster discovery cycles: Accelerate discovery cycles with AI-driven analytics and automation.

Improved traceability: Ensure compliance through end-to-end data provenance tracking.

Future-ready architecture: Support genomics, transcriptomics, proteomics, and other omics fields with a future-ready architecture.

“This partnership gives Ultima’s customers a direct path to combining world-class sequencing with equally powerful informatics,” said Andrew Wyatt, chief growth officer at Sapio Sciences. “By removing workflow complexity, we’re making it easier for labs to manage multi-omics data, gain insights faster, and scale without compromising quality or compliance.”

Sapio Sciences Partner Program

The Sapio Sciences Partner Program connects innovators with Sapio’s industry-leading lab informatics platform, fostering integrations that deliver measurable benefits to customers. It includes three partner ecosystems:

Technology partners: Hardware, cloud, and software vendors that extend the platform through integration, hosting, and solution development.

Services partners: Advisory and implementation experts who guide customers through lab automation and deployment.

Reseller partners: Value-Added Resellers (VARs) and consultants who resell Sapio solutions and add value through customization, integration, training, and support.

Discover how Sapio Sciences can revolutionize your lab operations at www.sapiosciences.com and follow us on LinkedIn.

Pharma industry news Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Edward Bartles on Future of Clinical Trials: IQVIA

Latest Pharma News - Record international attendance at CPHI & PMEC China 2025

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Global healthcare AI experts and former UK Health Minister back AI that detects healthcare-associated infections up to 72 hours earlier

Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research

Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research

Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins Made in the USA

GREENFIELD GLOBAL TAPS INDUSTRY VETERAN VEY GAROFALO TO DRIVE SPECIALTY CHEMICALS AND INGREDIENTS EXPANSION

datma Launches Federated Biomarker Explorer with Free Access to Help Pharma Validate Real-World Data Coverage.